NTRB
NutribandBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The bull case is that AVERSA Fentanyl and related transdermal IP can still create meaningful re-rating optionality if regulatory work keeps advancing, and the packet's median analyst target of $15 is far above the $3.55 anchor price.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
AVERSA Fentanyl still depends on clinical, manufacturing, and regulatory execution before it can contribute meaningful value.
Momentum
79
Value
41
Sentiment
56
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.10 · Bull $10.50 · Bear $1.70
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-02 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $15.00
Why
Momentum79 · Δ7d -
Value41 · Δ7d +0.1
Sentiment56 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
79
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
56
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 78.7 / Value 41.1 / Sentiment 55.8
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$43.15M
Beta
1.87
Shares Out
12.17M
P/E (TTM) · Derived
-3.6
P/S (TTM)
23.94
P/FCF (TTM) · Derived
-7.14
Rev YoY
-46.4%
EPS YoY
-161.7%
Gross Margin
+33.5%
Op Margin
-564.3%
Net Debt
-$4.13M
Current Ratio
7.53
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology